Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
Total Valuation
BriaCell Therapeutics has a market cap or net worth of C$26.64M. The enterprise value is -C$6.43M.
Market CapC$26.64M
Enterprise Value-C$6.43M
Share Statistics
BriaCell Therapeutics has 1,883,906 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,883,906
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BriaCell Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-1.66M
Employee Count16
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of BriaCell Therapeutics is ―. BriaCell Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow-1.54
PEG Ratio0.00
Income Statement
In the last 12 months, BriaCell Therapeutics had revenue of 0.00 and earned -36.50M in profits. Earnings per share was -86.25.
Revenue0.00
Gross Profit-147.89K
Operating Income-37.73M
Pretax Income-36.83M
Net Income-36.50M
EBITDA-36.63M
Earnings Per Share (EPS)-86.25
Cash Flow
In the last 12 months, operating cash flow was -28.17M and capital expenditures 0.00, giving a free cash flow of -28.17M billion.
Operating Cash Flow-28.17M
Free Cash Flow-28.17M
Free Cash Flow per Share-14.95
Dividends & Yields
BriaCell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.09
52-Week Price Change-92.00%
50-Day Moving Average15.39
200-Day Moving Average32.16
Relative Strength Index (RSI)65.12
Average Volume (3m)3.11K
Important Dates
BriaCell Therapeutics upcoming earnings date is Dec 10, 2025, TBA (Confirmed).
Last Earnings DateOct 15, 2025
Next Earnings DateDec 10, 2025
Ex-Dividend Date―
Financial Position
BriaCell Therapeutics as a current ratio of ―, with Debt / Equity ratio of 0.00%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, BriaCell Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
BriaCell Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
BriaCell Therapeutics has C$17.87M in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$17.87M billion.
Cash & Marketable SecuritiesC$17.87M
Total DebtC$0.00
Net CashC$17.87M
Net Cash Per ShareC$9.48
Tangible Book Value Per Share―
Margins
Gross margin is 0.00%, with operating margin of ―, and net profit margin of ―.
Gross Margin0.00%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for BriaCell Therapeutics is C$56.01, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$56.01
Price Target Upside304.70% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-81.77%